glp 1 clinical pearls GLP-1 Novel oral GLP-1 receptor agonist
Description
If you want weight-loss results that radiate out to your heart, liver, kidneys, sleep quality, and day-to-day comfort, GLP-1 therapy under Dr
Tirzepatide causes thyroid C-cell tumors in rats, and although its unknown whether tirzepatide causes thyroid C-cell tumors in humans, it is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Adults using a GLP-1 had an increase in GFR from 50.48 mL/min/1.73 m 2 at baseline to 53.44 mL/min/1.73 m 2 at 6 months, whereas the control group had a decrease from 43.4 mL/min/1.73 m 2 at baseline to 40.84 mL/min/1.73 m 2 at 6 months ( P = .03)
Nearly 50% of GLP-1 users said they didnt lose 20 pounds or more
However, reduced side effects at lower doses may also reflect reduced therapeutic effect
Over the past few years, a number of GLP-1 drugs targeting obesity and type 2 diabetes have received regulatory approvals globally
